滥用物质诱发的阶段性多巴胺释放需要大麻素受体激活。
Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.
作者信息
Cheer Joseph F, Wassum Kate M, Sombers Leslie A, Heien Michael L A V, Ariansen Jennifer L, Aragona Brandon J, Phillips Paul E M, Wightman R Mark
机构信息
Department of Chemistry and Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-3290, USA.
出版信息
J Neurosci. 2007 Jan 24;27(4):791-5. doi: 10.1523/JNEUROSCI.4152-06.2007.
Abstract
Transient surges of dopamine in the nucleus accumbens are associated with drug seeking. Using a voltammetric sensor with high temporal and spatial resolution, we demonstrate differences in the temporal profile of dopamine concentration transients caused by acute doses of nicotine, ethanol, and cocaine in the nucleus accumbens shell of freely moving rats. Despite differential release dynamics, all drug effects are uniformly inhibited by administration of rimonabant, a cannabinoid receptor (CB1) antagonist, suggesting that an increase in endocannabinoid tone facilitates the effects of commonly abused drugs on subsecond dopamine release. These time-resolved chemical measurements provide unique insight into the neurobiological effectiveness of rimonabant in treating addictive disorders.
摘要
伏隔核中多巴胺的短暂激增与药物寻求行为有关。我们使用具有高时间和空间分辨率的伏安传感器，证明了自由活动大鼠伏隔核壳中急性剂量的尼古丁、乙醇和可卡因所引起的多巴胺浓度瞬变的时间特征存在差异。尽管释放动力学不同，但所有药物效应均被大麻素受体（CB1）拮抗剂利莫那班的给药所一致抑制，这表明内源性大麻素张力的增加促进了常用滥用药物对亚秒级多巴胺释放的影响。这些时间分辨化学测量为利莫那班治疗成瘾性疾病的神经生物学有效性提供了独特见解。
相似文献
1
Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.
J Neurosci. 2007 Jan 24;27(4):791-5. doi: 10.1523/JNEUROSCI.4152-06.2007.
2
Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.
J Neurosci. 2004 May 5;24(18):4393-400. doi: 10.1523/JNEUROSCI.0529-04.2004.
3
Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake rats.
J Neurochem. 2006 May;97(4):1145-54. doi: 10.1111/j.1471-4159.2006.03860.x.
4
The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food.
Neurosci Lett. 2007 Jun 4;419(3):231-5. doi: 10.1016/j.neulet.2007.04.012. Epub 2007 Apr 8.
5
Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.
Neuropharmacology. 2012 Jun;62(7):2192-201. doi: 10.1016/j.neuropharm.2012.01.013. Epub 2012 Jan 25.
6
Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids.
Eur J Neurosci. 2016 Jun;43(12):1661-73. doi: 10.1111/ejn.13248. Epub 2016 May 11.
7
Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.
Neuropsychopharmacology. 2004 May;29(5):911-20. doi: 10.1038/sj.npp.1300370.
8
Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice.
Addict Biol. 2015 Jan;20(1):91-103. doi: 10.1111/adb.12080. Epub 2013 Aug 4.
9
Drug addiction.
Curr Top Behav Neurosci. 2009;1:309-46. doi: 10.1007/978-3-540-88955-7_13.
10
Involvement of the cannabinoid CB1 receptor in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats.
PLoS One. 2014 Mar 14;9(3):e92224. doi: 10.1371/journal.pone.0092224. eCollection 2014.
引用本文的文献
1
Reelin marks cocaine-activated striatal neurons, promotes neuronal excitability, and regulates cocaine reward.
Sci Adv. 2025 Mar 28;11(13):eads4441. doi: 10.1126/sciadv.ads4441. Epub 2025 Mar 26.
2
Elevating levels of the endocannabinoid 2-arachidonoylglycerol blunts opioid reward but not analgesia.
bioRxiv. 2024 Apr 2:2024.04.02.585967. doi: 10.1101/2024.04.02.585967.
3
Optimized Fabrication of Carbon-Fiber Microbiosensors for Codetection of Glucose and Dopamine in Brain Tissue.
ACS Sens. 2024 May 24;9(5):2662-2672. doi: 10.1021/acssensors.4c00527. Epub 2024 Apr 30.
4
Mobilization of endocannabinoids by midbrain dopamine neurons is required for the encoding of reward prediction.
Nat Commun. 2023 Nov 20;14(1):7545. doi: 10.1038/s41467-023-43131-3.
5
Dysregulation of the endogenous cannabinoid system following opioid exposure.
Psychiatry Res. 2023 Dec;330:115586. doi: 10.1016/j.psychres.2023.115586. Epub 2023 Nov 3.
6
G protein-coupled receptor modulation of striatal dopamine transmission: Implications for psychoactive drug effects.
Br J Pharmacol. 2024 Nov;181(22):4399-4413. doi: 10.1111/bph.16151. Epub 2023 Jun 20.
7
Decreased Ventral Tegmental Area CB1R Signaling Reduces Sign Tracking and Shifts Cue-Outcome Dynamics in Rat Nucleus Accumbens.
J Neurosci. 2023 Jun 21;43(25):4684-4696. doi: 10.1523/JNEUROSCI.1486-22.2023. Epub 2023 May 19.
8
Role of mesolimbic cannabinoid receptor 1 in stress-driven increases in cocaine self-administration in male rats.
Neuropsychopharmacology. 2023 Jul;48(8):1121-1132. doi: 10.1038/s41386-023-01589-1. Epub 2023 May 15.
9
Fatty Acid-Binding Protein 5 Gene Deletion Enhances Nicotine-Conditioned Place Preference: Illuminating the Putative Gateway Mechanisms.
Future Pharmacol. 2023 Mar;3(1):108-116. doi: 10.3390/futurepharmacol3010007. Epub 2023 Jan 9.
10
Acute and chronic effects by nicotine on striatal neurotransmission and synaptic plasticity in the female rat brain.
Front Mol Neurosci. 2023 Jan 12;15:1104648. doi: 10.3389/fnmol.2022.1104648. eCollection 2022.
本文引用的文献
1
Guidelines on nicotine dose selection for in vivo research.
Psychopharmacology (Berl). 2007 Feb;190(3):269-319. doi: 10.1007/s00213-006-0441-0. Epub 2006 Aug 9.
2
Two brain sites for cannabinoid reward.
J Neurosci. 2006 May 3;26(18):4901-7. doi: 10.1523/JNEUROSCI.3554-05.2006.
3
Region-specific effects of nicotine on brain activity: a pharmacological MRI study in the drug-naïve rat.
Neuropsychopharmacology. 2006 Aug;31(8):1690-703. doi: 10.1038/sj.npp.1300955. Epub 2005 Nov 16.
4
Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo.
Psychopharmacology (Berl). 2005 Dec;183(3):368-77. doi: 10.1007/s00213-005-0195-0. Epub 2005 Oct 15.
5
Critical assessment of how to study addiction and its treatment: human and non-human animal models.
Pharmacol Ther. 2005 Oct;108(1):18-58. doi: 10.1016/j.pharmthera.2005.06.018.
6
Real-time measurement of dopamine fluctuations after cocaine in the brain of behaving rats.
Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10023-8. doi: 10.1073/pnas.0504657102. Epub 2005 Jul 8.
7
Cannabinoid CB1 receptors control conditioned drug seeking.
Trends Pharmacol Sci. 2005 Aug;26(8):420-6. doi: 10.1016/j.tips.2005.06.002.
8
Endocannabinoid system and alcohol addiction: pharmacological studies.
Pharmacol Biochem Behav. 2005 Jun;81(2):369-80. doi: 10.1016/j.pbb.2005.01.022.
9
Endocannabinoid signaling system and brain reward: emphasis on dopamine.
Pharmacol Biochem Behav. 2005 Jun;81(2):263-84. doi: 10.1016/j.pbb.2005.01.032.
10
CB1 receptor antagonists for the treatment of nicotine addiction.
Pharmacol Biochem Behav. 2005 Jun;81(2):387-95. doi: 10.1016/j.pbb.2005.01.024.
Zotero 插件